Boston, MA 04/22/2014 (wallstreetpr) – Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) focuses largely on cancer research.
Innovations and Research
The company has witnessed promising preclinical results for RX-21101, its first development candidate obtained from its Nano-Polymer-Drug Conjugate System (NPDCS) platform. RX-21101 has showed enhanced tumor regression, complete tumor growth inhibition and extended survival in xenograft models.
Rexahn Pharmaceuticals Inc has come up with the initial data for the First Phase dose increment clinical trial of a new drug, Supinoxin(TM)(RX-5902). This research is still going on, and achievement of maximal tolerated dose (MTD) is still awaited. Three dosing cycles of 25, 50 and 100 mg have been completed so far. Not a single drug related adverse event has been reported so far. The fourth cycle of 150 mg dose has been initiated.
The company has initiated a Phase Ib clinical trial to study in depth the safety and efficacy of RX-3117 in patients suffering from cancer and having solid tumors. This trial is a dose escalation study which is being done to evaluate the tolerability, safety and maximal tolerated dose (MTD) of this drug in such patients.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has been granted a patent, EP 1546180 by the European Patent Office for its clinical development molecule Archexin. It finds use in inhibiting the activated form of Akt-1 (phospho-Akt1) for cancer treatment. Initiation of Phase II clinical trial to study the safety and efficacy of the drug in patients suffering from metastatic renal cell carcinoma (RCC) has been done. Archexin had earlier been granted Orphan Drug Designation for RCC indication. Top line results from Phase 2 study of Archexin have been announced by the company.
Some institutional investors have expressed an interest to buy $5.3 million of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s securities. Rexahn went into a securities purchase contract with these investors. Following this deal, Rexahn has agreed to sell off 10.2 million shares of its common stock.
U.S. Patent and Trademark Office has issued patent for quinazoline compounds, method for producing antitumor effect and their composition.
